Skip to main content
. 2023 Apr 5;4(3):80–90. doi: 10.1016/j.cvdhj.2023.03.002

Table 1.

Baseline characteristics

All
Excellent ECG quality sample
P value
(n = 290) (n = 189)
Age (years) 67.0 (55.3–74.0) 67.0 (56.0–75.0) .925
Female 138 (47.6) 85 (45.0) .273
Reason for ECG
 New symptoms 173 (59.7) 105 (55.6) .069
 Cardiovascular risk management 31 (10.7) 23 (12.2) .360
 Known diabetes mellitus 47 (16.2) 34 (18.0) .337
 Known ischemic heart disease 14 (4.8) 13 (6.9) .052
 Known heart rhythm disorder 6 (2.1) 4 (2.1) 1.000
 Other 19 (6.6) 10 (5.3) .348
Symptoms§
 Palpitations 74 (25.5) 39 (20.6) .014
 Chest pain 64 (22.1) 44 (23.3) .595
 Dyspnea 37 (12.8) 24 (12.7) 1.000
 Light-headedness 23 (7.9) 12 (6.3) .256
 Fatigue 26 (9.0) 17 (9.0) 1.000
 (Near) collapse 12 (4.1) 6 (3.2) .414
 Other 31 (10.7) 18 (9.5) .497
Hypertension 123 (42.4) 79 (41.8) .741
Heart failure 12 (4.1) 7 (3.7) .843
Diabetes mellitus 85 (29.3) 60 (31.7) .339
Prior stroke/TIA 18 (6.2) 13 (6.9) .694
Atrial fibrillation 30 (10.3) 23 (12.2) .233
Other arrhythmia 13 (4.5) 9 (4.8) .987
Valvular disease 13 (4.5) 10 (5.3) .540
Hypercholesterolemia 68 (23.4) 44 (23.3) 1.000
Peripheral vascular disease 22 (7.6) 17 (9.0) .314
Coronary heart disease 30 (10.3) 20 (10.6) 1.000
COPD 30 (10.3) 16 (8.5) .278
Chronic kidney disease 30 (10.3) 18 (9.5) .315
Beta-blocker use 57 (19.7) 37 (19.6) 1.000
Sodium channel blocker use 4 (1.4) 2 (1.1) .910
Potassium channel blocker use 2 (0.7) 2 (1.1) .770
Calcium channel blocker use 43 (14.8) 28 (14.8) 1.000
Digoxin use 2 (0.7) 2 (1.1) .770

Data are number (percentage) or median (interquartile range). P value is for difference between excellent (n = 189) and non-excellent (n = 101) ECG quality sample.

COPD = chronic obstructive pulmonary disease; ECG = electrocardiogram; IQR = interquartile range; TIA = transient ischemic attack.

Excellent ECG quality was defined as no or mild noise and/or up to 1 lead with baseline drift.

Patients were assessed as having 1 (primary) reason for ECG.

§

Patients could report multiple symptoms at baseline, and symptoms were not mutually exclusive.